Viral infections – pipeline review, h2 2012


Published on

2012 | || Viral infections – pipeline review, h2 2012

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Viral infections – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Viral Infections – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Viral Infections - Pipeline Review, H2 2012, provides anoverview of the indication’s therapeutic pipeline. This report provides informationon the therapeutic development for Viral Infections, complete with latest updates,and special features on late-stage and discontinued projects. It also reviews keyplayers involved in the therapeutic development for Viral Infections. Viral Infections- Pipeline Review, Half Year is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Viral Infections.- A review of the Viral Infections products under development by companies anduniversities/research institutes based on information derived from company and
  2. 2. industry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.Reasons to buy- Identify and understand important and diverse types of therapeutics underdevelopment for Viral Infections.- Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.Table of contents:List of Tables 13List of Figures 18Introduction 19Global Markets Direct Report Coverage 19Viral Infections Overview 20Therapeutics Development 21An Overview of Pipeline Products for Viral Infections 21Viral Infections Therapeutics under Development by Companies 23Viral Infections Therapeutics under Investigation by Universities/Institutes 36Late Stage Products 43Comparative Analysis 43Mid Clinical Stage Products 44Comparative Analysis 44Early Clinical Stage Products 45Comparative Analysis 45Discovery and Pre-Clinical Stage Products 46Comparative Analysis 46Viral Infections Therapeutics – Products under Development by Companies 47Viral Infections Therapeutics – Products under Investigation byUniversities/Institutes 63Companies Involved in Viral Infections Therapeutics Development 78Bristol-Myers Squibb Company 78Vical Incorporated 79
  3. 3. United Therapeutics Corporation 80Shionogi & Co., Ltd. 81List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1Multiple Myeloma (Kahlers Disease) – Pipeline Review, H2 2012Respiratory Depression – Pipeline Review, H2 2012Metastatic Cancer – Pipeline Review, H2 2012Viral Infections – Pipeline Review, H2 2012Central Nervous System (CNS) Cancer – Pipeline Review, H2 2012 Gastrointestinal Tract Cancer – Pipeline Review, H2 2012 Diabetes – Pipeline Review, H2 2012 Chronic Lymphocytic Leukemia (CLL) – Pipeline Review, H2 2012 Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) – Pipeline Review,H2 2012
  4. 4. Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2012 Malaria – Pipeline Review, H2 2012 Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections – Pipeline Review,H2 2012 Dermatitis – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: